Evidence map›Paper›PMID 36428484›Full record

ArticleBiomedicines2022

Altered Immunomodulatory Responses in the CX3CL1/CX3CR1 Axis Mediated by hMSCs in an Early In Vitro SOD1

Anastasia Sarikidi, Ekaterini Kefalakes, Christine S Falk, Ruth Esser, Arnold Ganser, Nadine Thau-Habermann, Susanne Petri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Anastasia SarikidiDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Ekaterini KefalakesDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0001-5074-9480
Christine S FalkInstitute of Transplant Immunology, Hannover Medical School, 30625 Hannover, Germany.
Ruth EsserInstitute of Cellular Therapeutics, Hannover Medical School, 30625 Hannover, Germany.
Arnold GanserInstitute of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Nadine Thau-HabermannDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Susanne PetriDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Medizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron (MN) disease characterized by progressive MN loss and muscular atrophy resulting in rapidly progressive paralysis and respiratory failure. Human mesenchymal stem/stromal cell (hMSC)-based therapy has been suggested to prolong MN survival via secretion of growth factors and modulation of cytokines/chemokines. We investigated the effects of hMSCs and a hMSC-conditioned medium (CM) on Cu/Zn superoxidase dismutase 1

Indexed as

amyotrophic lateral sclerosisfractalkinehuman mesenchymal stem/stromal cellsmotor neuronsSOD1G93A

Identifiers

PMID36428484
PMCPMC9688016
OpenAlexW4309003314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.